PARSIPPANY, N.J., Feb. 21, 2017 /PRNewswire/ -- Interpace
Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" or the
"Company"), a fully integrated commercial company that provides
clinically useful molecular diagnostic tests and pathology
services, today announced the initiation of a collaborative
research program with Viatar CTC Solutions Inc. (Viatar), the
cancer dialysis company.
The collaboration utilizes Viatar's novel circulating tumor cell
collection technology in combination with the Company's
commercialized PancraGEN™ assay that is used to help assess
indeterminate pancreatic cancer biopsies in patients with
pancreatic cysts. Studies are being designed to identify patients
most likely to develop pancreatic cancer in the near future as well
as to detect pancreatic cancer at its earliest stage of
development.
These pre-clinical studies are expected to take place over the
next six months and may lead to the implementation of early
diagnostic testing and assessment for patients with pancreatic
diseases and/or for those predisposed to the development of this
aggressive and difficult to treat form of cancer most in need of
early and accurate detection.
According to Jack E. Stover
President & CEO of Interpace Diagnostics, "We are
pleased to partner with Viatar, a company dedicated to CTC's and in
combination with our PancraGEN assay we are hopeful of providing
early detection, prognosis and disease monitoring by way of liquid
biopsies for pancreatic cancer at its earliest stage of detection.
"
About Interpace Diagnostics Group
Interpace is a fully integrated commercial company that provides
clinically useful molecular diagnostic tests and pathology services
for evaluating risk of cancer by leveraging the latest technology
in personalized medicine for better patient diagnosis and
management. The Company currently has three commercialized
molecular tests: PancraGEN®, for the evaluation of pancreatic cysts
and assessment of risk of concomitant or subsequent cancer;
ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules
utilizing a next generation sequencing assay; and ThyraMIR®, for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
proprietary gene expression assay. Interpace's mission is to
provide personalized medicine through molecular diagnostics and
innovation to advance patient care based on rigorous science. For
more information, please visit Interpace Diagnostics' website at
www.interpacediagnostics.com
About PancraGEN®
PancraGEN® is a pancreatic cyst molecular test
that, by using a small sample of pancreatic cyst fluid, can aid in
pancreatic cancer risk assessment. PancraGEN® is
90% accurate, according to clinical studies, enabling effective
risk stratification of patients. Pancreatic cancer is often
difficult to diagnose in early stages and typically spreads rapidly
with signs and symptoms appearing when the cancer is significantly
advanced. Because of this, and that complete surgical removal of
the pancreas is not possible, pancreatic cancer is considered a
leading cause of cancer deaths.
About Viatar CTC Solutions
Viatar CTC Solutions Inc., the cancer dialysis company, is a
medical technology company focused on the treatment of patients
with metastatic cancer. The company's lead product, the
Viatar® Oncopheresis System, removes circulating tumor cells
from liters of whole blood based on a patented filtration method
using size and stiffness. Pending regulatory approval, it
will be used as a periodic dialysis-like therapy for a wide range
of solid tumor types such as lung, breast, colon, prostate,
pancreatic and gastric cancers. This proprietary technology also
powers the company's liquid biopsy products, which are collection
systems for use by genetic testing companies, researchers and
medical oncologists that provide a greater quantity and purity of
circulating tumor cells for their molecular analysis and
personalized medicine objectives. For additional information
about Viatar, go to www.viatarctcsolutions.com.
FORWARD-LOOKING STATEMENTS:
This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995, relating to the Company's future financial and
operating performance. The Company has attempted to identify
forward looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "projects,"
"intends," "potential," "may," "could," "might," "will," "should,"
"approximately" or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control.
These statements also involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from those expressed or implied
by any forward-looking statement. Known and unknown risks,
uncertainties and other factors include, but are not limited to,
the Company's ability to adequately finance the business, its
ability to restructure its debt and other obligations, the market's
acceptance of its molecular diagnostic tests, its ability to secure
additional business and generate higher profit margins through
sales of its molecular diagnostic tests, in-licensing or other
means, projections of future revenues, growth, gross profit and
anticipated internal rate of return on investments and our ability
to maintain our NASDAQ listing. Additionally, all forward-looking
statements are subject to the risk factors detailed from time to
time in the Company's filings with the SEC, including without
limitation, the Annual Report on Form 10-K filed with the SEC on
March 30, 2016, as amended on
April 29, 2016 and June 14, 2016, the Quarterly Report on Form 10-Q
filed with the SEC on November 17,
2016, and the prospectus supplement and accompanying
prospectus related to the offering that was filed with the SEC.
Because of these and other risks, uncertainties and assumptions,
undue reliance should not be placed on these forward-looking
statements. In addition, these statements speak only as of the date
of this press release and, except as may be required by law, the
Company undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:
Victor Roberts
RedChip Companies
407.644.4256, ext. 111
victor@redchip.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-enters-into-collaborative-agreement-with-viatar-ctc-solutions-to-detect-and-characterize-early-cancer-in-liquid-biopsies-300410597.html
SOURCE Interpace Diagnostics Group, Inc.